Stocks and Investing
Stocks and Investing
Wed, December 16, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Initiated (AXSM) at Strong Buy and Held Target at $120 on, Dec 16th, 2020
Vamil Divan of Mizuho, Initiated "Axsome Therapeutics, Inc." (AXSM) at Strong Buy and Held Target at $120 on, Dec 16th, 2020.
Vamil has made no other calls on AXSM in the last 4 months.
There is 1 other peer that has a rating on AXSM. Out of the 1 peers that are also analyzing AXSM, 0 agree with Vamil's Rating of Hold.
This is the rating of the analyst that currently disagrees with Vamil
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $101 on, Monday, November 9th, 2020
Contributing Sources